TissueScan, Lymphoma cDNA Array I

SKU
LYRT301
TissueScan Lymphoma Tissue qPCR Panel I (5) containing five identical sets of 48 tissues covering four disease stages and normal tissues
  $1,870.00
In Stock*
Specifications
Specifications
Product Data
TissueScan Type Cancer Specific
Clinical Info
Diagnosis Category Lymphoma
Tissue Lymphoid tissue
Shipping Ambient
Description TissueScan Lymphoma Tissue qPCR Panel I (5) containing five identical sets of 48 tissues covering four disease stages and normal tissues
Reviews
 
 
 
 
 

Be the first to review this product

Please note:
Only reviews with images are eligible for a $20/20€ Amazon gift card.
Reviews without images are eligible for a $10/10€ Amazon gift card.
For more details about the terms and conditions, please visit the promotion page.

Review image
Documents
Resources

file-alt Citations

Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
Friedman, Garrett, Evans et al
Hum. Gene Ther. (2018) 29 (5), 585-601 DOI: 10.1089/hum.2018.001
AI Summary: OriGene’s TissueScan™ Cancer cDNA Array (LYRT301) was used in this study to assess BCMA gene expression across various lymphoma samples, enabling the researchers to quantify BCMA levels and support the targeting of BCMA-expressing malignancies by CAR T cells.
Snippet: Lymphoma cDNA Array (LYRT301) plates were purchased from the TissueScan Cancer cDNA Array (OriGene Technologies). Quantitative polymerase chain reactions (qPCR) were run on the StepOnePlus Real-Time PCR System (Applied Biosystems) using TaqMan Gene Expression Master Mix (Applied Biosystems) and assay primer/probe set (Hs03045080_m1 for TNFRSF17 [BCMA];Applied Biosystems), according to the manufacturer's instructions. The ΔCt was calculated for each sample against the endogenous control gene (Hs99999903_m1 for ACTB;Applied Biosystems), which provides normalization for each cDNA sample
Effective Targeting of Multiple BCMA-Expressing Hematological Malignancies by Anti-BCMA CAR T Cells
Friedman, Garrett, Evans et al
Human Gene Therapy (2018)
AI Summary: OriGene's TissueScan™ Cancer cDNA Array (LYRT301) was used in this study to quantify BCMA mRNA levels in tumor samples, aiding in the analysis of BCMA expression across hematological malignancies.
Snippet: al published versio n may differ fro m this proof. Quantitation of BCMA mRNA levels in tumors Lymphoma cDNA Array (LYRT301) plates were purchased from the TissueScan Cancer cDNA Array (OriGene Technologies). qPCR reactions were run on the StepOnePlus
Acidosis Decreases c-Myc Oncogene Expression in Human Lymphoma Cells: A Role for the Proton-Sensing G Protein-Coupled Receptor TDAG8
Li, Dong, Dean et al
Int J Mol Sci (2013) 14 (10), 20236-55 DOI: 10.3390/ijms141020236
Cited by 49
AI Summary: OriGene’s human lymphoma tissue cDNA arrays were used in this study to analyze TDAG8 gene expression in lymphoma samples via real-time RT-PCR, enabling the authors to compare TDAG8 levels between tumor and non-tumorous tissues.
Snippet: (A,B) Human lymphoma tissue cDNA arrays (OriGene Technologies) were subject to real-time RT-PCR using TDAG8 specific primer probes. β-actin was used as an internal control for normalization. ... Lymphoma tissue cDNA arrays were purchased from OriGene
Showing 1-3 of 3 papers.
Powered by BizGenius
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Related Products